Cadrenal Therapeutics, Inc. Share Price & Technical Analysis
CVKD · $5.19 (+0.39%)
Healthcare / Biotechnology
$5.19
+0.39%
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patien…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 4 years shown)
-25% return in May, -3% avg return in past 3 year May month.
-18% return in 2026, -23% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -8% | 25% | -41% | 31% | -25% | – | – | – | – | – | – | – | -18% |
| 25 | 34% | -5% | -7% | -7% | -19% | -9% | -15% | 27% | 10% | -2% | -31% | -25% | -49% |
| 24 | 144% | -66% | -13% | -31% | 8% | -4% | -8% | 15% | 77% | 20% | -4% | -6% | 129% |
| 23 | -51% | -29% | -31% | 0% | 2% | 9% | -43% | -12% | -9% | -37% | 6% | 48% | -148% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$15.93M
P/E ratio
—
52W high
$15.99
52W low
$4.21
Volume
1,01,834
Beta
1.83
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cadrenal Therapeutics, Inc. share price today?
- Cadrenal Therapeutics, Inc. (CVKD) last traded around $5.19 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CVKD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CVKD. Download the app for real-time alerts.
- How can I analyze Cadrenal Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.